Biannual Account of Anti‐malarial Agents reported in 2021 and 2022: A Comprehensive Coverage
Tejas M. Dhameliya, D. Patel, Deepika Kathuria, Maitri B. Shah, Akshada Dabhade, Hetvi Dave, Nidhi C. Lad, Amit Z. Chaudhari, Shahnaz Alom, Vivek K. Vyas, Hardik Bhatt
Abstract
Abstract Malaria remains a severe infectious disease caused by Plasmodium parasites among the primarily afflicting impoverished populations. According to World Health Organization (WHO) report, there were an estimated 247 million malarial cases globally, resulting in approximately 6,19,000 fatalities. Particularly prevalent in tropical and subtropical regions, the development of drug resistance has exacerbated this public health challenge. Consequently, there has been a concrete effort to explore novel compounds with anti‐malarial properties. In continuation of our previous works, this review focuses on heterocyclic compounds documented in 2021 and 2022, including artemisinin, benzimidazole, benzofuran, β‐lactam, coumarin, furan, indole, morpholine, piperazine, pyrimidine, quinoline, triazole, etc. highlighting their efficacy, structural characteristics, in vitro and in vivo activities, among other relevant aspects for the broad interest of medicinal chemists working on the design and development of novel anti‐malarial agents.